Drug intelligence / Profile preview

sulfonylurea + pioglitazone + liraglutide

Development stage: Unknown
Lead developer: Novo Nordisk
Modality: Peptides, Small Molecules
Administration: Oral, Subcutaneous

Overview

A triple combination therapy for type 2 diabetes mellitus that combines three different mechanisms of action. Sulfonylureas stimulate insulin secretion from pancreatic beta cells, pioglitazone improves insulin sensitivity by activating PPAR-gamma receptors, and liraglutide is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion and suppresses glucagon secretion. This combination has shown significant efficacy in improving glycemic control in patients with poorly controlled diabetes.

Targets

SUR1 (Sulfonylurea receptor 1)PPARG (Peroxisome proliferator-activated receptor gamma)GLP1R (GLP-1R)

Beyond the preview

Go deeper on sulfonylurea + pioglitazone + liraglutide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sulfonylurea + pioglitazone + liraglutide.

Explore the full profile